CTIBIOTECH Launches US Operations with $27 Million Investment to Advance 3D Bioprinting for Drug Development
核心洞察
CTIBIOTECH (搜索) officially launched its North American subsidiary CTIBIOTECH USA (搜索) with a $27 million investment, establishing operations in Philadelphia's "Cellicon Valley" biotechnology hub.
The company aims to address the 95% failure rate of new cancer drugs in clinical trials by providing 3D bioprinted human tissue models including microtumors and skin models for drug testing.
The expansion includes $12 million for US operations over five years and $15 million in intellectual property assets to accelerate personalized medicine development.
CTIBIOTECH (搜索), a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, officially launched its North American subsidiary CTIBIOTECH USA (搜索) with a $27 million investment. The launch took place at the SelectUSA (搜索) Investment Summit in Washington, D.C., marking a significant expansion into the North American pharmaceutical market.
Strategic Investment in Philadelphia's Biotechnology Hub
Operating from Philadelphia's "Cellicon Valley" life sciences hub in association with BioLabs for Advanced Therapeutics (搜索), CTIBIOTECH USA (搜索) will provide proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. The expansion represents a $12 million investment in U.S. operations over the next five years, alongside an additional $15 million investment in intellectual property assets.
Addressing Critical Drug Development Challenges
Professor Colin McGuckin, President and Chief Scientific Officer of CTIBIOTECH (搜索), highlighted the urgent need for improved drug testing methods: "Currently, 95% of new cancer drugs fail during human clinical trials, costing the industry billions and delaying life-saving treatments. The launch of CTIBIOTECH USA (搜索) marks a crucial step toward solving this global health challenge."
The company's revolutionary 3D bioprinting technologies include microtumor and human skin models that provide researchers with highly predictive, human-derived biological assays for testing new therapies and advancing personalized medicine.
Accelerating Drug Discovery Through Localized Innovation
Dr. Nico Forraz, Chief Executive Officer of CTIBIOTECH (搜索), emphasized the strategic importance of the U.S. expansion: "This comprehensive strategic investment in operations and intellectual property positions us to drastically accelerate the drug discovery process for our North American partners. By establishing our proprietary manufacturing and contract research capabilities here in the U.S., we are eliminating the geographic challenges of international research and delivering immediate, localized innovation to the North American pharmaceutical ecosystem."
Innovative Tissue Engineering Technology
Founded in 2009 in Lyon, France, CTIBIOTECH (搜索) specializes in creating functional 3D human tissues by upcycling human surgical tissues that are normally discarded, giving them new life to advance biomedical research. The company operates an ISO 9001-certified human tissue biobank for research use only with a capacity of over 50,000 clinical samples, providing integrated drug discovery, development, and innovation solutions globally while drastically reducing the industry's reliance on animal testing.
Government and Industry Support
The successful establishment of CTIBIOTECH USA (搜索) resulted from extensive transatlantic collaboration. The official launch featured remarks from distinguished leaders including Thomas Bruns, Deputy Director General of the U.S. & Foreign Commercial Service Global Markets; David Briel, Senior Managing Director of International Trade & Investment for the Pennsylvania Department of Community and Economic Development; and Lindsey Hover of the Chamber of Commerce for Greater Philadelphia.
The company acknowledges support from the US Federal Government's SelectUSA (搜索), the State of Pennsylvania, the City of Philadelphia, and the Chamber of Commerce of Greater Philadelphia, as well as ongoing backing from French and European partners including Business France (搜索), BPI France (搜索), and various regional organizations.